

In this issue

Research Article

[Open Access](#) [Research Article](#) PTZAID:AOT-7-119

The efficacy of SARS-CoV-2 antibody response after two dose mRNA vaccination in kidney and heart transplant recipients using a multiplex bead-based assay: Evaluating the factors affecting vaccine response

Published On: May 25, 2022 | Pages: 001 - 008

Author(s): Steven J Forte, Angela J Toepp, Robert A Bray, David A Baran, Lauren T Gilgannon, Troy Williams, Shirui Chen, Hooman Sadr, Howard M Gebel, John M Herre and Thomas R McCune*

Background: The extent that which immunosuppressive factors contribute to the antibody response to SARS-Cov-2 vaccination in solid organ transplant patients is being better understood. This study examined antibody formation against the spike SARS-CoV-2 protein (SA) when full vaccinations were up to 2 doses and boosters were not recommended. Immunosuppressive factors t ...

[Abstract View](#) [Full Article View](#) [DOI: 10.17352/2640-7973.000019](#)

Case Report

[Open Access](#) [Case Report](#) PTZAID:AOT-7-120

Contrary to expectation: Preserved renal function after using PD-1 Inhibitor Cemiplimab-rwlc in a kidney transplant recipient

Published On: September 08, 2022 | Pages: 009 - 010

Author(s): Muhannad Leghrouz*, Svetomir N Markovic and Aleksandra Kukla

The use of immune checkpoint inhibitors in transplant recipients with malignancy is associated with the risk of graft failure due to acute rejection. There is limited literature regarding the use of Cemiplimab-rwlc (Libtayo) in kidney transplant patients. Here we present a case of using Cemiplimab-rwlc (Libtayo), a Programmed Death receptor-1 (PD-1) blocking antibody ...

[Abstract View](#) [Full Article View](#) [DOI: 10.17352/2640-7973.000020](#)